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Summary
 
Self-antigens, in the form of differentiation antigens, are commonly recognized by the immune
system on melanoma and other cancers. We have shown previously that active immunization
of mice against the melanocyte differentiation antigen, a tyrosinase-related protein (TRP)
gp75
 
TRP-1
 
 (the 
 
brown
 
 locus protein) expressed by melanomas, could induce tumor immunity
and autoimmunity manifested as depigmentation. In this system, tumor immunity and autoim-
munity were mediated by autoantibodies. Here, we characterize immunity against another ty-
rosinase family glycoprotein TRP-2 (the 
 
slaty
 
 locus protein), using the same mouse model and
method of immunization. As observed previously for gp75
 
TRP-1
 
, immunity was induced by
DNA immunization against a xenogeneic form of TRP-2, but not against the syngeneic gene,
and depended on CD4
 
1
 
 cells. Immunization against TRP-2 induced autoantibodies and au-
toreactive cytotoxic T cells. In contrast to immunization against gp75
 
TRP-1
 
, both tumor immu-
nity and autoimmunity required CD8
 
1
 
 T cells, but not antibodies. Only autoimmunity re-
quired perforin, whereas tumor immunity proceeded in the absence of perforin. Thus,
immunity induced against two closely related autoantigens that are highly conserved through-
out vertebrate evolution involved qualitatively different mechanisms, i.e., antibody versus
CD8
 
1
 
 T cell. However, both pathways led to tumor immunity and identical phenotypic man-
ifestations of autoimmunity.
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S
 
elf-antigens on human cancer are the most prevalent an-
tigens recognized by the immune system (1). This re-
flects the fact that cancers arise from the hosts’ own tissues,
and are not truly foreign. Thus, in some respects, immune
recognition of cancer appears to be different from immune
recognition of viruses or bacteria, and typically more akin
to autoimmunity. Recognition of self-antigens on cancer
presents problems. First, immunity to cancer may not de-
velop because of immune tolerance. Second, even when
the immune system can recognize and respond to self-anti-
gens, immunity may not be sufficient to reject cancers. Fi-
nally, if immunity to self-antigens develops, there are po-
tential autoimmune sequelae.
Differentiation antigens form one prototype of self-anti-
gens on cancer (2–4). A differentiation antigen distin-
guishes a cell lineage from other cell types, and is typically
expressed at specific stages of differentiation (5). Immune
recognition of human cancer has been intensively investi-
gated in melanoma, a cancer arising from melanocytes (1).
Studies of melanoma have surprisingly shown that the im-
mune system commonly recognizes products of genes that
are specifically expressed by melanocytes, particularly genes
that are involved in synthesis of pigment (1, 6). Examples
include tyrosinase, the critical enzyme required for synthe-
sis of the pigment melanin, and tyrosinase-related proteins
(TRPs) that determine the type of melanin synthesized
(TRP-2 and gp75
 
TRP-1
 
) [3, 4, 7]). These melanoma/melano-
cyte differentiation antigens can be recognized by antibod-
ies and by CD8
 
1
 
 and CD4
 
1
 
 T cells, and thus can be broadly
seen by the immune system (3, 4, 7–18).
We have reported previously that immunization of
C57BL/6 mice against the tyrosinase family antigen
gp75
 
TRP-1
 
 induces tumor immunity and autoimmunity that
is mediated by autoantibodies (13, 15–17). Using DNA
immunization strategies, we have investigated immunity
induced against another homologous tyrosinase family
member, TRP-2. The mouse gp75
 
TRP-1
 
 and TRP-2 pro-
teins are closely related, having 52% identity and 67%
homology, and these genes have been highly conserved
throughout vertebrate evolution (e.g., the identity of mouse
gp75
 
TRP-1
 
 and chicken TRP-2 is also 52%).
 
W.B. Bowne and R. Srinivasan share first authorship on this paper. 
1718
 
Coupling and Uncoupling of Tumor Immunity and Autoimmunity
 
Materials and Methods
 
Mice.
 
C57BL/6 mice (6–8-wk-old females) were acquired
through the National Cancer Institute breeding program. Homo-
zygotic mice genetically deficient for 
 
b
 
2-microglobulin (
 
b
 
2m
 
2
 
/
 
2
 
),
MHC II (Abb
 
2
 
/
 
2
 
), and perforin (B6.
 
pfp
 
2
 
/
 
2
 
), all in a C57BL/6
background, were obtained from Taconic Farms, Inc. Immuno-
globulin 
 
m
 
 chain (
 
m
 
MT
 
2
 
/
 
2
 
) and 
 
gld
 
/
 
gld
 
 (B6.
 
gld
 
) mice were acquired
from The Jackson Laboratory. These mice were bred and kept in a
pathogen-free Memorial Sloan-Kettering Cancer Center vivarium
according to National Institutes of Health Animal Care guidelines.
All mice entered the study between 7 and 10 weeks of age.
 
Cell Lines and Tissue Culture.
 
B16F10/LM3 (15) is a pig-
mented mouse melanoma cell line of C57BL/6 origin, derived
from the B16F10 line, provided by Dr. Isaiah Fidler (M.D.
Anderson Cancer Center, Houston, TX). The EL-4 cell line was
derived from a C57BL/6 mouse lymphoma, and SK-MEL-188 is
a human melanoma cell line. Tumor cell lines were cultured as
described (15).
 
Plasmid Constructs.
 
The human TRP-2 (hTRP-2) and mouse
TRP-2 (mTRP-2) expression vectors (supplied by Drs. S.A.
Rosenberg and J.C. Yang, National Cancer Institute, Bethesda,
MD) were previously described (9). These genes were cloned
into the PCR3 vector, which was used as a control vector with-
out inserts. The mouse GM-CSF gene, provided by PowderJect
Vaccines Inc., was cloned into the WRGBEN vector (13).
 
DNA Immunization.
 
The method of DNA immunization has
been reported (13). In brief, plasmid DNA encoding hTRP-2,
mTRP-2, or GM-CSF was coated onto 1.0 
 
m
 
m gold bullets. An-
imals were immunized by delivering gold–DNA complexes using
a helium-driven gun (Accell
 
®
 
; PowderJect Vaccines Inc.) into
each abdominal quadrant (1 
 
m
 
g plasmid DNA/quadrant) for a to-
tal of four injections.
 
Depletion and Depigmentation Studies.
 
NK cell depletion was
performed as described (15). Animals were injected intraperito-
neally with mAb PK136 (anti–NK-1.1) 3 d before immunization,
and every 4 d thereafter. Depigmentation experiments were per-
formed as described (13, 15). In brief, after the final immuniza-
tion, mice were shaved and depilated over the posterior flank and
observed for 8 wk. Scoring of depigmentation was performed by
dividing the abdomen into four equal quadrants. Quadrants were
recorded as positive when they had estimated 
 
.
 
50% depig-
mented hairs. Depigmentation was scored 0–4
 
1
 
 according to the
number of quadrants that were depigmented in each mouse (e.g.,
3
 
1
 
 if three of four quadrants are depigmented 
 
.
 
50%).
 
Antibody Responses to TRP-2.
 
Antibody responses to synge-
neic mTRP-2 were measured by immunoprecipitation, followed
by Western blot assay as described (13). B16F10/LM3 melanoma
cells were lysed, followed by immunoprecipitation with anti–PEP-8,
a rabbit polyclonal antisera raised against a carboxyl-terminal pep-
tide of TRP-2 (from Vincent Hearing, National Cancer Insti-
tute).
 
CTL Assay.
 
Lymphocytes (2 
 
3
 
 10
 
7
 
) from draining inguinal
lymph nodes were cocultured for 5 d with naive irradiated (3,000
rads) splenocytes (2 
 
3
 
 10
 
7
 
), mitomycin C (100 
 
m
 
g/ml, 120 min
at 37
 
8
 
C)-treated human SK-MEL-188 cells (4 
 
3
 
 10
 
5
 
) as a source
of antigen, and pristane-induced macrophages (2 
 
3
 
 10
 
6
 
) from
C57BL/6 mice. H-2K
 
b
 
–restricted lymphocyte lysis of EL-4 tu-
mor cells pulsed for 1 h at 37
 
8
 
C with 4 
 
m
 
g mTRP-2
 
181–188
 
 pep-
tide (sequence VYDFFVWL) was determined by a 4-h standard
 
51
 
Cr release assay (16).
 
Mouse Tumor Studies.
 
All mice were injected intravenously
via the tail vein with 2 
 
3
 
 10
 
5
 
 B16F10/LM3 melanoma cells. Tu-
mor challenge was performed 5 d after the final immunization,
unless otherwise indicated. Mice were killed at 14–22 d after tu-
mor challenge, all lobes of both lungs were dissected, and surface
lung metastases were scored and counted for all lobes under a dis-
secting microscope. Statistical analysis of tumor growth was per-
formed using the two-sided Student’s 
 
t
 
 test, assuming unequal
variances and Wilcoxon Scores (Rank Sums).
Figure 1. Protection and re-
jection of mouse melanoma
B16F10/LM3 after immunization
with human TRP-2 (hTRP-2),
but not mouse TRP-2 (mTRP-2)
DNA. C57BL/6 mice, 10–12 per
group, were immunized cutane-
ously with hTRP-2 or mTRP-2
DNA by particle bombardment.
Mice were challenged with B16
melanoma cells intravenously and
scored for surface lung metastases
after 14–17 d. (A and B) Mice
were immunized three times at
weekly intervals with hTRP-2,
mTRP-2, or PCR3 control
vector (vector), and compared
to untreated mice. Mice were
challenged with B16F10/LM3
melanoma 5 d after the last im-
munization. B is a repeat of the
experiment in A, without the vector control and mTRP-2 groups. Significant tumor protection was observed in both experiments (P , 0.0001). (C)
Mice were immunized five times at weekly intervals with hTRP-2, or mTRP-2, or were untreated. Significant protection was observed with hTRP-2
compared with no treatment (P 5 0.001) or with mTRP-2 (P 5 0.001). The difference between mice treated with mTRP-2 and untreated mice was
not significant (P 5 0.16). (D) Immunization with hTRP-2 DNA started 4 d after tumor challenge, or mice remained untreated. A significant therapeu-
tic effect was observed (P , 0.001). (E) Immunization with hTRP-2 plus GM-CSF DNA started 10 d after tumor challenge. Significant therapeutic ef-
fect was observed compared with other treatment and control groups (P , 0.01). GM-CSF treatment alone yielded 692 6 69 metastases, mTRP-2 gave
902 6 65 metastases, hTRP-2 gave 783 6 75 metastases, and control null vector gave 705 6 61 metastases (not shown in figure). Results are shown as
mean number of lung metastases 6 SEM. 
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Results
 
Xenogeneic, but Not Syngeneic, TRP-2 DNA Induces Tumor
Rejection.
 
hTRP-2 has 90% homology and 83% identity
to the amino acid sequence of C57BL/6 mTRP-2. DNA
immunization with xenogeneic hTRP-2 decreased B16F10/
LM3 lung metastases by 
 
$
 
90% (
 
P
 
 
 
,
 
 0.0001) in tumor pro-
tection experiments (Fig. 1, A–C). There was no signifi-
cant evidence of tumor immunity after immunization with
syngeneic mTRP-2 DNA compared with untreated mice
or mice injected with control null vector (Fig. 1, A and C).
To assess the potency of DNA immunization using xe-
nogeneic hTRP-2 DNA, mice were immunized 4 d after
tumor challenge or 10 d after tumor challenge, when lung
metastases were numerous and macroscopic. Immunization
at 4 d decreased metastases by 
 
.
 
80% (
 
P
 
 
 
,
 
 0.001; Fig. 1 D).
Therapeutic effects were observed 10 d after tumor chal-
lenge using immunization with hTRP-2 DNA plus recom-
binant mouse GM-CSF DNA as an immune adjuvant.
Vaccination significantly decreased lung metastases by ap-
proximately half (
 
P
 
 
 
5
 
 0.004; Fig. 1 E). No significant de-
crease in lung metastases was observed after treatment with
hTRP-2 or mTRP-2 DNA, or GM-CSF DNA alone (Fig.
1 E, see legend), although there was a trend towards de-
creased metastases with GM-CSF alone that did not reach
significance (
 
P
 
 
 
.
 
 0.05). These results showed a require-
ment for xenogeneic antigen and the adjuvant effect of
GM-CSF in the treatment of established tumors.
 
Xenogeneic hTRP-2 DNA Vaccination Induces Autoantibod-
ies and Autoreactive CTLs.
 
We next determined whether
immunization with mTRP-2 or xenogeneic hTRP-2 gen-
erated antibody and CD8
 
1
 
 T cell responses against synge-
neic mTRP-2. 6 of 12 mice immunized with hTRP-2 had
detectable IgG antibodies (IgG1 and IgG2b isotype) against
mTRP-2 (data not shown). No autoantibodies against syn-
geneic mouse TRP-2 were generated after immunization
with mTRP-2 (0/12). Generation of autoantibodies after
immunization with hTRP-2 required both CD4
 
1
 
 and
CD8
 
1
 
 T cells, because no autoantibodies were detected in
mice deficient in MHC class I (0/11) or II molecules (0/10).
CTL responses against TRP-2 were detected after im-
munization with xenogeneic hTRP-2, but not syngeneic
mTRP-2 DNA. Specifically, CD8
 
1
 
 CTL from draining
lymph nodes (supraclavicular nodes), stimulated in vitro for
5 d, recognized an MHC class I H-2K
 
b
 
–restricted peptide of
mTRP-2 after immunization with hTRP-2 DNA (Fig. 2
[9]). Interestingly, the H-2K
 
b
 
–restricted peptide of mTRP-2,
mTRP-2
 
181–188
 
, is identical between mouse and human
TRP-2, including the immediate flanking amino acid resi-
dues. Thus, this self-peptide in the context of self–TRP-2
DNA does not induce CTL responses, but presentation of
the same peptide in the context of xenogeneic hTRP-2 is
immunogenic.
 
Tumor Rejection Requires CD4
 
1
 
 and CD8
 
1
 
 Cells, but Not
B Cells or NK Cells.
 
These results suggested that either
antibody or CTL responses, or both, mediated tumor re-
jection. Roles for critical cell types were investigated by
immunizing 
 
b
 
2m
 
2
 
/
 
2
 
 mice deficient in MHC class I and
CD8
 
1
 
 T cells, MHC II
 
2
 
/
 
2
 
 mice deficient in MHC class II
and CD4
 
1
 
 T cells, Ig
 
m
 
2
 
/
 
2
 
 mice deficient in mature B cells,
and mice depleted of NK1.1
 
1
 
 cells, including NK cells
(Fig. 3). Both MHC class I and II molecules were required
for tumor rejection, supporting a central role for both
CD8
 
1
 
 and CD4
 
1
 
 T cells. Neither NK cells nor B cells
were necessary for tumor immunity. Noticeably, mice de-
ficient in B cells developed fewer baseline metastases com-
pared with wild-type C57BL/6 mice, and were completely
free of any detectable tumor after treatment with hTRP-2
(12 of 12 mice). This phenomenon of enhanced T cell–
dependent tumor rejection associated with B cell deficiency
has been reported previously (10). These results showed that
T cell immunity, including both CD8
 
1
 
 and CD4
 
1
 
 T cells,
was required for tumor rejection, but antibodies were not.
 
Xenogeneic Immunization Induces Autoimmunity That Also
Requires T Cells.
 
Signs of autoimmunity, manifested as
depigmentation, were observed in mice immunized with
hTRP-2, but not generally in mice immunized with syn-
geneic mTRP-2 (Fig. 4). Depigmentation appeared 4–5
wk after starting immunization over depilated and shaved
areas of the mouse coat, spreading to unshaved areas in most
mice. Autoimmunity also required T cells, but not antibod-
ies or NK cells, showing that tumor immunity and autoim-
munity were coupled by a requirement for class I and II
MHC expression leading to a requirement for T cells.
 
Requirement for Perforin in T Cell–dependent Autoimmunity,
but Not Tumor Immunity. CTLs have been proposed to be
critical effector cells that mediate tumor rejection. Cyto-
toxicity of T cells can be mediated by exocytic granules in-
Figure 2. CTL response to
TRP-2181–188 peptide in mice
that were not immunized (A), or
immunized with mTRP-2 (B) or
hTRP-2 (C). C57BL/6 mice (2
or 3 per group) were immunized
as described in the legend to
Fig. 1. 7 d after the last immuni-
zation, draining lymph nodes
were pooled and stimulated as
described in Materials and Meth-
ods for 5 d and tested for cyto-
toxicity against EL-4 target cells,
either pulsed with TRP-2 pep-
tide or unpulsed. Results are rep-
resentative of two experiments.1720 Coupling and Uncoupling of Tumor Immunity and Autoimmunity
volving perforin, or by cell membrane molecules that in-
duce death of target cells. Tumor immunity proceeded in
the complete absence of perforin (P 5 0.0002) in pfp2/2
mice (Fig. 5), whereas autoimmunity was mostly inhibited
(Fig. 4). Fas ligand was not necessary for either autoimmu-
nity (Fig. 4) or tumor immunity (Fig. 5). These results are
consistent with perforin-mediated killing of normal mela-
nocytes in hair follicles playing a central role in autoimmu-
nity. However, tumor immunity could proceed in a per-
forin-independent manner.
Discussion
TRP-2 is recognized by CTLs of patients with mela-
noma (7, 11, 12), and has also been defined as a potential
tumor-rejection antigen in C57BL/6 mice (9). Thus,
TRP-2 provides a model for a differentiation antigen with
relevance to a human cancer. Xenogeneic DNA vaccina-
tion is one strategy to immunize against potentially weak
self-antigens. The approach using a xenogeneic source of
antigen is well known to produce autoimmunity, but has
also been used to induce tumor immunity against gp75TRP-1
and another melanocyte/melanoma differentiation antigen
gp100 (13, 14, 16–18). Other strategies have shown that
syngeneic mouse gp75TRP-1 expressed in insect cells (16) or
by vaccinia virus (14) can also induce tumor immunity and
trigger depigmentation. Expression of the syngeneic pro-
tein in the context of xenogeneic cells that may package
the antigen in insoluble inclusion bodies (e.g., insect cells)
or with strongly immunogenic viral proteins are alternative
strategies, at least for inducing antibody-dependent immu-
nity against tyrosinase family antigens.
As noted above, the CTL response directed against the
H-2Kb-restricted peptide of mTRP-2, mTRP-2181–188, is
remarkable because this peptide is identical between mouse
and human TRP-2, including the immediate flanking amino
acid residues. It is possible the distant amino acid residues al-
ter processing of this peptide in hTRP-2, allowing more ef-
ficient presentation. Alternatively, amino acid differences in
other peptides of hTRP-2 may provide T cell help, which
in turn is sufficient to trigger CTL responses to the mTRP-
2181–188 self-peptide. The observation that only hTRP-2
DNA (but not mTRP-2 DNA) induced CD81 T cell re-
sponses suggests that T cell tolerance was broken by xenoge-
neic DNA immunization, although we recognize this could
reflect differences in efficiency of processing.
Tumor Immunity and Autoimmunity: Two Means to the
Same End. Immunity against gp75TRP-1 led to tumor pro-
tection and to depigmentation that was indistinguishable
from autoimmunity induced by immunization against
TRP-2 (13). Similar results were observed by Naftzger et al.
(16) and Overwijk et al. (14) after immunization with syn-
geneic gp75TRP-1 expressed by baculovirus in insect cells or
in vaccinia virus, respectively. In gp75TRP-1 systems, tumor
immunity and autoimmunity were mediated by autoanti-
Figure 3. Tumor rejection in C57BL/6 mice deficient in immune
molecules and cells. Mice, 10–12 per group, were immunized cutane-
ously with hTRP-2 DNA as described in the legend to Fig. 1. Lung me-
tastases were evaluated after 18 d. Groups included mice deficient in b2
microglobulin (b22/2), MHC II, immunoglobulins (m2/2), and depleted
of NK1.11 cells (NK deplete). All mice were treated in the same experi-
ment, and differences in lung metastases in the no treatment groups reflect
tumorigenicity in different mouse strains or under different conditions
(e.g., NK deplete). Significant protection was observed in NK depleted
(P , 0.0001) and m2/2 (P 5 0.03), but not b22/2 or MHC II2/2
(P . 0.10) mice. This experiment is representative of two experiments.
Results are shown as mean 6 SEM.
Figure 4. Depigmentation in mice treated with hTRP-2 or mTRP-2
DNA. Groups of mice (12–15 per group) were immunized with hTRP-2
or mTRP-2 DNA as described in the legend to Fig. 1, or remained un-
treated. Each dot represents a separate mouse. Groups include C57BL/6
(wt) mice treated with hTRP-2 (h) or mTRP-2 (m) DNA. In addition,
immunoglobulin-deficient (m2/2), b2 microglobulin-deficient (b22/2),
MHC II–deficient (MHC II2/2), NK-depleted, and perforin-deficient
(perf2/2) mice were immunized with hTRP-2.
Figure 5. Tumor rejection in perforin-deficient (pfp2/2) mice and gld/gld
mice (deficient in fas ligand) treated with hTRP-2, compared with mice
not treated. Mice (9 or 10 per group) were immunized cutaneously with
hTRP-2 DNA as described in the legend to Fig. 1. Significant tumor protec-
tion was observed in pfp2/2 (P 5 0.0002) and gld/gld (P , 0.0001) mice.1721 Bowne et al. Brief Definitive Report
bodies, and tumor immunity depended on NK cells and
functional Fc receptors; neither tumor immunity nor au-
toimmunity required CD81 T cells (13–17). In contrast,
tumor immunity and autoimmunity against TRP-2 re-
quired MHC class I molecules, and by implication CD81
T cells, without a requirement for antibodies or NK cells.
Thus, either autoantibodies or T cells can provide specific-
ity for tumor immunity and autoimmunity.
Antibody Versus CD81 T Cells: Both Need CD41 Cells.
The final phenotype of tumor immunity and autoimmu-
nity can be dependent either on antibodies or CD81 T
cells, but in both cases CD41 cells are required. Vaccina-
tion against TRP-2 as late as 10 d after tumor challenge in-
duced substantial decreases in tumor burden, whereas ac-
tive immunization against gp75TRP-1 at these later time
points was ineffective (13). We propose that this reflects in
part the kinetics of T cell versus antibody responses, where
effective T cell immunity can be generated over days,
whereas effective antibodies may require weeks. Passive
transfer of antibodies against gp75TRP-1 had significant ef-
fects 4 and 7 d after tumor challenge (15), consistent with
this view.
Tumor Immunity and Autoimmunity. The potential cou-
pling of tumor immunity with autoimmunity has been
suggested by the clinical observation that patients with
metastatic melanoma who develop vitiligo have a better
prognosis and are more likely to respond to therapy (19–
22). The differences in mechanisms underlying tumor im-
munity and autoimmunity could be a consequence of fun-
damental differences in effector mechanisms used to kill
tumor cells versus normal melanocytes. Alternatively, the
differences could reflect the different tissue sites of melano-
cytic cells. In this scenario, the effector mechanisms in the
skin require perforin, whereas other mechanisms are used
in the lung. Mechanisms other than perforin or fas ligand
may be involved in tumor rejection, but it is also possible
that perforin and fas ligand provide redundant mechanisms
for effector functions against tumors. Finally, the uncou-
pling of tumor immunity from autoimmunity in this model
shows that one can inhibit autoimmunity and still be per-
missive for tumor immunity. This opens strategies for in-
ducing immunity to treat cancer where autoimmunity can
be inhibited while cancer immunity proceeds.
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